HeartBeam reports Q2 EPS (19c), two estimates (16c)

Cash and cash equivalents totaled $9.2M as of June 30, 2024, compared to $16.2M as of December 31, 2023. “The second quarter of 2024 was highlighted by new data for the validation of HeartBeam AI, our deep learning technology, and ongoing progress with anticipated regulatory and clinical milestones for the AIMIGo vector technology platform,” said Branislav Vajdic, PhD, Chief Executive Officer and Founder of HeartBeam. “We have successfully resolved the vast majority of questions the FDA has asked and are in the process of providing the additional information the FDA requested during the quarter. We are engaged in productive discussions with the FDA and believe that we are progressing toward clearance, which we anticipate later this year. We have created our initial Go-To-Market plan and will be testing this during our limited launch prior to the end of the year.”